Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The European Respiratory Journal|March 26, 2026
Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trialMarlies S Wijsenbeek, Shervin Assassi, Arata Azuma, et al.
The European Respiratory Journal|September 3, 2021
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trialKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
The New England Journal of Medicine|October 1, 2019
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R Flaherty, Athol U Wells, Vincent Cottin, et al.
ERJ Open Research|June 24, 2021
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung diseaseRobin Deterding, Matthias Griese, Gail Deutsch, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Progressive Pulmonary FibrosisToby M Maher, Shervin Assassi, Arata Azuma, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Pageof 7